Biomm

Brazilian biotechnology company founded in 2001 and listed on B3, developing, manufacturing and marketing biopharmaceuticals with the stated aim of giving Brazil production independence in insulin analogues and other biologics. Its Nova Lima plant in Minas Gerais covers 50,000 square metres. It markets Glargilin, Herzuma, Afrezza, Wosulin and Ghemaxan in diabetes and oncology, partnering with Gan & Lee, Bioton, MannKind and Celltrion.